RNS Number : 4729K
Haleon PLC
12 April 2024
 

Icon Description automatically generated

 

 

Haleon plc: Notice of Annual General Meeting (AGM)

 

12 April 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following documents have been made available to shareholders:

 

1.  Notice of 2024 Annual General Meeting (the "Notice")

2.  Form of Proxy for 2024 Annual General Meeting

3.  AGM Voting Instruction Card

 

The Company's AGM will be a virtual meeting, broadcast under studio conditions from the Company's London offices at 3.00pm (BST) on Wednesday 8 May 2024. The Notice is available on the Company's website at http://www.haleon.com/investors/shareholder-information/annual-general-meetings, and includes full details of the business to be conducted and joining instructions.

In compliance with Listing Rule 9.6.1, a copy of the above documents has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Amanda Mellor, Company Secretary

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAGPUPACUPCGUP